Join Here   |   Log In

CYP2C19 Genetic Variant Impact Medications (SSRIs, Blood Thinners) and Toxins

Key takeaways:
~ The CYP2C19 gene is important in how your body responds to medications and breaks down toxins.
~ Variants in the CYP2C19 gene impact your response to medications such as omeprazole, clopidogrel, diazepam, and certain SSRIs.
Members will see their genotype report below and the solutions in the Lifehacks section. Consider joining today

CYP2C19: Important for SSRIs, blood thinners

CYP2C19 is a member of the CYP450 family of enzymes that breaks down drugs, toxins, and other substances naturally produced in your body. (Learn more about other detoxification genes.)

The CYP2C19 enzyme is responsible for the breakdown (also called metabolism) of several popular drugs, including proton pump inhibitors (omeprazole, esomeprazole, lansoprazole), certain anti-epileptics, and an antiplatelet drug (clopidogrel).

Several important CYP2C19 genetic variants impact how drugs break down, causing some people to be poor metabolizers and others to be fast metabolizers.

You can have increased side effects (depending on the medication) either from being a slow metabolizer or a fast metabolizer.

Some medications, called pro-drugs, need to break down into their metabolites for the drug to be effective. Other drugs clear your system through the use of the CYP enzymes. Thus, the effect of a variant depends on the specific medication.

Here’s an example of the activation of the pro-drug clopidogrel (a blood thinner) by the CYP2C19 enzyme. Without a functioning CYP2C19 enzyme, the active thiol form of clopidogrel won’t be formed and thus blood clots will still be able to form.

Clopidogrel pathway using CYP2C19 to activate the prodrug into the active drug. Pathway from ClinPGx.

CYP2C19 medication example:

Clinical trials clearly show that genetic variants (SNPs) in CYP2C19 can affect how people react to different medications.

  • A CYP2C19 fast metabolizer taking omeprazole to treat h. pylori may have an insufficient response because the drug may not remain active in the body long enough.[ref]
  • Alternatively, pro-drugs, such as clopidogrel, convert into their active drug state through CYP2C19. If you are a poor metabolizer, it could mean clopidogrel (an anticoagulant) isn’t activated enough, and you wouldn’t be protected from blood clots.[ref]
  • Diazepam is another common drug metabolized partly by CYP2C19 (along with the CYP3A4 enzyme). Currently, there are no official recommendations to physicians as to reducing the dosages for poor metabolizers, but there is a box warning about CYP2C19.[ref]
  • Some SSRIs, citalopram, sertraline, and escitalopram, also metabolize mainly through CYP2C19.[ref]
  • A 2021 study showed that the average dose of citalopram is not as effective as an antidepressant for people with one copy of a non-functioning CYP2C19 variant (rs4244285).[ref]

CYP2C19 Poor Metabolizers:

You can your genetic data below to see if you are likely to be a poor metabolizer or have reduced CYP2C19 function. The frequency of poor metabolizers varies quite a bit by ancestry group:

  • Approximately 10 – 20% of Asians are poor metabolizers, as are 2 – 5% of people of Caucasian descent.
  • Up to 20-30% of Caucasians are fast metabolizers, but less than 5% of Asians are.

Medications metabolized by CYP2C19:

Many different medications are metabolized at least in part by CYP2C19.

The most important interaction is with clopidogrel (Plavix). People who have non-functioning CYP2C19 variants aren’t able to turn the pro-drug into the active form that acts as a blood thinner. This is a problem after heart surgery when someone depends on clopidogrel to block the formation of blood clots.  CPIC Guidelines

Other commonly used drugs metabolized by CYP2C19 include:[ref]

  • voriconazole (antifungal) – CPIC guidelines for CYP2c19
  • citalopram (SSRI)
  • escitalopram (SSRI)
  • sertraline (SSRI)
  • moclobemide (MAOA inhibitor)
  • diazepam (anxiety, epilepsy)
  • mephenytoin (epilepsy)
  • phenytoin (epilepsy)
  • phenobarbital (epilepsy)
  • primidone(epilepsy)
  • methylphenobarbital (epilepsy)
  • lansoprazole (proton pump inhibitors)
  • omeprazole (proton pump inhibitors)
  • pantoprazole (proton pump inhibitors)
  • propranolol (beta blocker)
  • tamoxifen (estrogen blocker)

You can check for less common gene X drug interactions on DrugBank Online. 

Talk with your doctor or pharmacist before making any changes to a medication that you are currently taking. Some medications can be metabolized through alternate routes and still work fine for someone with CYP2C19 variants.

Natural supplements that interact with CYP2C19:

Environmental toxins:

CYP2C19 is also involved in the metabolism of certain environmental toxins. When CYP enzymes break down toxins, the metabolite formed is often also toxic and needs to be quickly eliminated using phase II detoxification.

Diazinon is an organophosphate pesticide bioactivated by CYP2C19.[ref]

People with low CYP2C19 activity alongside higher CYP2B6 activity are more likely to have AChE activity inhibition with exposure to organophosphate pesticides (chlorpyrifos).[ref]

Endogenous substances metabolized by CYP2C19:

While we often focus on the interactions with drug metabolism, the CYP2C19 enzyme is found naturally in the body to break down several hormones that are endogenously produced.

  • CYP2C19 helps to activate and break down some hormones, such as progesterone.[ref]
  • It is involved (minor) in metabolizing melatonin[ref]
  • It is also involved in the metabolism of estradiol.[ref]

Note that CYP2C19 is not the only route for metabolizing these hormones, just one way that the body can break them down.


CYP2C19 Genotype Report:

Members: Log in to see your data below.
Not a member? Join here.

Access this content:

An active subscription is required to access this content.

Join as a member


 


Lifehacks:

Lifestyle interactions:

Stop smoking:
If you are a CYP2C19 poor metabolizer and a smoker, you have a 5x increased risk of lung cancer[ref] and a 17x increased risk of laryngeal cancer.[ref]  Other studies show that CYP2C19 poor metabolizers are more likely to have esophageal cancer with smoking or pickled vegetable consumption.[ref]

Pharmacogenetic testing for antidepressants:

Access this content:

An active subscription is required to access this content.

Join as a member



Related Articles and Topics:

CYP2A6: Breaking down nicotine and other medications

CYP2C9: Genetic Variants and Drug Metabolism

CYP3A4 Gene: Impacting Prescription Drugs

Phase I and Phase II Detoxification Pathways Explained


References:

Akiyoshi, Takeshi, et al. “Analysis of Inhibition Kinetics of Three Beverage Ingredients, Bergamottin, Dihydroxybergamottin and Resveratrol, on CYP2C9 Activity.” Drug Metabolism and Pharmacokinetics, vol. 42, Feb. 2022, p. 100429. PubMed, https://doi.org/10.1016/j.dmpk.2021.100429.
Chen, Xiao-Ping, et al. “Isozyme-Specific Induction of Low-Dose Aspirin on Cytochrome P450 in Healthy Subjects.” Clinical Pharmacology and Therapeutics, vol. 73, no. 3, Mar. 2003, pp. 264–71. PubMed, https://doi.org/10.1067/mcp.2003.14.
Cheng, Z. N., et al. “Role of Cytochrome P450 in Estradiol Metabolism in Vitro.” Acta Pharmacologica Sinica, vol. 22, no. 2, Feb. 2001, pp. 148–54.
“ClinPGx.” ClinPGx, https://www.clinpgx.org/pathway/PA154424674. Accessed 17 Feb. 2026.
CPIC® Guideline for Clopidogrel and CYP2C19 – CPIC. https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/. Accessed 17 Feb. 2026.
CPIC® Guideline for Voriconazole and CYP2C19 – CPIC. https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/. Accessed 17 Feb. 2026.
Dean, Laura. “Diazepam Therapy and CYP2C19 Genotype.” Medical Genetics Summaries, edited by Victoria M. Pratt et al., National Center for Biotechnology Information (US), 2012. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK379740/.
Dean, Laura, and Megan Kane. “Omeprazole Therapy and CYP2C19 Genotype.” Medical Genetics Summaries, edited by Victoria M. Pratt et al., National Center for Biotechnology Information (US), 2012. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK100895/.
Ellison, Corie A., et al. “Human Hepatic Cytochrome P450-Specific Metabolism of the Organophosphorus Pesticides Methyl Parathion and Diazinon.” Drug Metabolism and Disposition, vol. 40, no. 1, Jan. 2012, p. 1. pmc.ncbi.nlm.nih.gov, https://doi.org/10.1124/dmd.111.042572.
Feng, J., et al. “Interaction between CYP 2C19*3 Polymorphism and Smoking in Relation to Laryngeal Carcinoma in the Chinese Han Population.” Genetics and Molecular Research: GMR, vol. 10, no. 4, Dec. 2011, pp. 3331–37. PubMed, https://doi.org/10.4238/2011.December.5.9.
Foxenberg, Robert J., et al. “Cytochrome P450-Specific Human PBPK/PD Models for the Organophosphorus Pesticides: Chlorpyrifos and Parathion.” Toxicology, vol. 285, nos. 1–2, July 2011, pp. 57–66. PubMed Central, https://doi.org/10.1016/j.tox.2011.04.002.
Hicks, JK, et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.” Clinical Pharmacology and Therapeutics, vol. 98, no. 2, Aug. 2015, pp. 127–34. PubMed Central, https://doi.org/10.1002/cpt.147.
Miyazawa, Mitsuo, et al. “Metabolism of (+)- and (-)-Limonenes to Respective Carveols and Perillyl Alcohols by CYP2C9 and CYP2C19 in Human Liver Microsomes.” Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 30, no. 5, May 2002, pp. 602–07. PubMed, https://doi.org/10.1124/dmd.30.5.602.
Mohos, Violetta, et al. “Inhibitory Effects of Quercetin and Its Main Methyl, Sulfate, and Glucuronic Acid Conjugates on Cytochrome P450 Enzymes, and on OATP, BCRP and MRP2 Transporters.” Nutrients, vol. 12, no. 8, July 2020, p. 2306. PubMed, https://doi.org/10.3390/nu12082306.
Peng, Xian-E., et al. “Independent and Combined Effects of Environmental Factors and CYP2C19 Polymorphisms on the Risk of Esophageal Squamous Cell Carcinoma in Fujian Province of China.” BMC Medical Genetics, vol. 16, Mar. 2015, p. 15. PubMed, https://doi.org/10.1186/s12881-015-0156-3.
Rastogi, Himanshu, and Snehasis Jana. “Evaluation of Inhibitory Effects of Caffeic Acid and Quercetin on Human Liver Cytochrome P450 Activities.” Phytotherapy Research: PTR, vol. 28, no. 12, Dec. 2014, pp. 1873–78. PubMed, https://doi.org/10.1002/ptr.5220.
Salminen, Kaisa A., et al. “Time-Dependent Inhibition of CYP2C19 by Isoquinoline Alkaloids: In Vitro and In Silico Analysis.” Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 43, no. 12, Dec. 2015, pp. 1891–904. PubMed, https://doi.org/10.1124/dmd.115.065755.
Yan, Fei, et al. “Interaction between Smoking and CYP2C19*3 Polymorphism Increased Risk of Lung Cancer in a Chinese Population.” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, vol. 35, no. 6, June 2014, pp. 5295–98. PubMed, https://doi.org/10.1007/s13277-014-1689-3.
Zastrozhin, M. S., et al. “Effects of CYP2C19 Genetic Polymorphism on the Steady-State Concentration of Citalopram in Patients with Major Depressive Disorder.” The Pharmacogenomics Journal, vol. 21, no. 4, Aug. 2021, pp. 435–39. www.nature.com, https://doi.org/10.1038/s41397-021-00219-7.
Zubiaur, Pablo, et al. “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally.” Advances in Therapy, vol. 36, no. 10, Oct. 2019, pp. 2744–55. Springer Link, https://doi.org/10.1007/s12325-019-01075-5.
http://www.snpedia.com/index.php/Rs4244285. Accessed 17 Feb. 2026.
http://www.snpedia.com/index.php/Rs4986893. Accessed 17 Feb. 2026.
http://www.snpedia.com/index.php/Rs12248560. Accessed 17 Feb. 2026.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.